Peripheral CD4+CD25+ TREG Cell Counts and the Response to Extracorporeal Photopheresis in Lung Transplant Recipients

2007 ◽  
Vol 39 (1) ◽  
pp. 213-217 ◽  
Author(s):  
F. Meloni ◽  
A. Cascina ◽  
S. Miserere ◽  
C. Perotti ◽  
P. Vitulo ◽  
...  
Keyword(s):  
Treg Cell ◽  
Lung Transplant ◽  
Extracorporeal Photopheresis ◽  
Transplant Recipients ◽  
Cell Counts ◽  
Lung Transplant Recipients

scholarly journals Outcome of Extracorporeal Photopheresis as an Add-On Therapy for Antibody-Mediated Rejection in Lung Transplant Recipients

2020 ◽  
Vol 47 (3) ◽  
pp. 205-213
Author(s):  
Alberto Benazzo ◽  
Nina Worel ◽  
Stefan Schwarz ◽  
Ulrike Just ◽  
Anna Nechay ◽  
...  
Keyword(s):  
Lung Transplantation ◽  
Lung Transplant ◽  
De Novo ◽  
Hla Class I ◽  
Class Ii ◽  
Class I ◽  
Extracorporeal Photopheresis ◽  
Transplant Recipients ◽  
Antibody Mediated Rejection ◽  
Lung Transplant Recipients

Introduction: The diagnosis and treatment of antibody-mediated rejection (AMR) after lung transplantation has recently gained recognition within the transplant community. Extracorporeal photopheresis (ECP), currently used to treat chronic lung allograft dysfunction, modulates various pathways of the immune system known to be involved in AMR. We hypothesize that adding ECP to established AMR treatments could prevent the rebound of donor-specific antibodies (DSA). Objectives: This study aimed to analyze the role of ECP as an add-on therapy to prevent the rebound of DSA. Methods: Lung transplant recipients who received ECP as an add-on therapy for pulmonary AMR between January 2010 and January 2019 were included in this single-center retrospective analysis. Baseline demographics of the patients, as well as their immunological characteristics and long-term transplant outcomes, were analyzed. Results: A total of 41 patients developed clinical AMR during the study period. Sixteen patients received ECP as an add-on therapy after first-line AMR treatment. Among the 16 patients, 2 (13%) had pretransplant DSA, both against human leukocyte antigen (HLA) class I (B38, B13, and C06). Fifteen patients (94%) developed de novo DSA (dnDSA), i.e., 10 (63%) against class I and 14 (88%) against class II. The median time to dnDSA after lung transplantation was 361 days (range 25–2,548). According to the most recent International Society of Heart and Lung Transplantation (ISHLT) consensus report, 2 (13%) patients had definite clinical AMR, 6 (38%) had probable AMR, and 7 (44%) had possible AMR. The median mean fluorescence intensity (MFI) of dnDSA at the time of clinical diagnosis was 4,220 (range 1,319–10,552) for anti-HLA class I and 10,953 (range 1,969–27,501) for anti-HLA class II antibodies. ECP was performed for a median of 14 cycles (range 1–64). MFI values of dnDSA against HLA classes I and II were significantly reduced over the treatment period (for anti-class I: 752; range 70–2,066; for anti-class II: 5,612; range 1,689–21,858). The 1-year survival rate was 55%. No adverse events related to ECP were reported in any of the patients. Conclusions: ECP is associated with a reduction of dnDSA in lung transplant recipients affected by AMR. Prospective studies are warranted to confirm the beneficial effects of ECP in the setting of AMR.

scholarly journals Efficacy of extracorporeal photopheresis in clearance of antibodies to donor-specific and lung-specific antigens in lung transplant recipients

2014 ◽  
Vol 33 (9) ◽  
pp. 950-956 ◽  
Author(s):  
Gautam Baskaran ◽  
Venkataswarup Tiriveedhi ◽  
Sabarinathan Ramachandran ◽  
Aviva Aloush ◽  
Brenda Grossman ◽  
...  
Keyword(s):  
Lung Transplant ◽  
Extracorporeal Photopheresis ◽  
Transplant Recipients ◽  
Specific Antigens ◽  
Lung Transplant Recipients

scholarly journals Cytokine levels in pleural fluid as markers of acute rejection after lung transplantation

2014 ◽  
Vol 40 (4) ◽  
pp. 425-428
Author(s):  
Priscila Cilene León Bueno de Camargo ◽  
José Eduardo Afonso Jr ◽  
Marcos Naoyuki Samano ◽  
Milena Marques Pagliarelli Acencio ◽  
Leila Antonangelo ◽  
...  
Keyword(s):  
Pleural Fluid ◽  
Lung Transplant ◽  
Transplant Recipients ◽  
Time Points ◽  
Cell Counts ◽  
Acute Graft Rejection ◽  
Cytokine Levels ◽  
Differential Cell ◽  
Lung Transplant Recipients ◽  
Acute Graft

Our objective was to determine the levels of lactate dehydrogenase, IL-6, IL-8, and VEGF, as well as the total and differential cell counts, in the pleural fluid of lung transplant recipients, correlating those levels with the occurrence and severity of rejection. We analyzed pleural fluid samples collected from 18 patients at various time points (up to postoperative day 4). The levels of IL-6, IL-8, and VEGF tended to elevate in parallel with increases in the severity of rejection. Our results suggest that these levels are markers of acute graft rejection in lung transplant recipients.

Lung transplant recipients on long-term extracorporeal photopheresis

2017 ◽  
Vol 31 (10) ◽  
pp. e13041 ◽  
Author(s):  
Bruno Isenring ◽  
Cécile Robinson ◽  
Urs Buergi ◽  
Macé M. Schuurmans ◽  
Malcolm Kohler ◽  
...  
Keyword(s):  
Lung Transplant ◽  
Extracorporeal Photopheresis ◽  
Transplant Recipients ◽  
Lung Transplant Recipients
Sign in / Sign up

Export Citation Format

Share Document